U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C27H44O3
Molecular Weight 416.6375
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 2
Charge 0

SHOW SMILES / InChI
Structure of CALCITRIOL

SMILES

C[C@]([H])(CCCC(C)(C)O)[C@@]1([H])CC[C@@]2([H])/C(=C(\[H])/C(/[H])=C\3/C[C@]([H])(C[C@@]([H])(C3=C)O)O)/CCC[C@]12C

InChI

InChIKey=GMRQFYUYWCNGIN-NKMMMXOESA-N
InChI=1S/C27H44O3/c1-18(8-6-14-26(3,4)30)23-12-13-24-20(9-7-15-27(23,24)5)10-11-21-16-22(28)17-25(29)19(21)2/h10-11,18,22-25,28-30H,2,6-9,12-17H2,1,3-5H3/b20-10+,21-11-/t18-,22-,23-,24+,25+,27-/m1/s1

HIDE SMILES / InChI

Molecular Formula C27H44O3
Molecular Weight 416.6375
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 6 / 6
E/Z Centers 2
Optical Activity UNSPECIFIED

Description
Curator's Comment:: description was created based on several sources, including: https://www.drugs.com/cdi/calcitriol.html http://www.wikidoc.org/index.php/Calcitriol_(oral)

Calcitriol is vitamin D3. Vitamin D is important for the absorption of calcium from the stomach and for the functioning of calcium in the body. Calcitriol is used to treat hyperparathyroidism (overactive parathyroid glands) and metabolic bone disease in people who have chronic kidney failure and are not receiving dialysis. Calcitriol is also used to treat calcium deficiency (hypocalcemia). The early signs and symptoms of vitamin D intoxication associated with hypercalcemia include: weakness, headache, somnolence, nausea, vomiting, dry mouth, constipation, muscle pain, bone pain and metallic taste. Cholestyramine has been reported to reduce intestinal absorption of fatsoluble vitamins; as such it may impair intestinal absorption of Calcitriol. Ketoconazole may inhibit both synthetic and catabolic enzymes of calcitriol.

CNS Activity

Curator's Comment:: Circulating calcitriol can cross the blood brain barrier to a limited extent, and the brain itself may be able to synthesize calcitriol.

Originator

Curator's Comment:: First obtained from chick intestine and designated as metabolite 4B

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ROCALTROL

Approved Use

Predialysis Patients Calcitriol Capsules are indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (Ccr 15 to 55 mL/min) not yet on dialysis. In children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. A serum iPTH level of ≥100 pg/mL is strongly suggestive of secondary hyperparathyroidism. Dialysis Patients Calcitriol Capsules are indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. In these patients, calcitriol administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. Hypoparathyroidism Patients Calcitriol Capsules are also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism.

Launch Date

2.72159998E11
Preventing
ROCALTROL

Approved Use

Predialysis Patients Calcitriol Capsules are indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (Ccr 15 to 55 mL/min) not yet on dialysis. In children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. A serum iPTH level of ≥100 pg/mL is strongly suggestive of secondary hyperparathyroidism. Dialysis Patients Calcitriol Capsules are indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. In these patients, calcitriol administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. Hypoparathyroidism Patients Calcitriol Capsules are also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism.

Launch Date

2.72159998E11
Primary
VECTICAL

Approved Use

VECTICAL Ointment is indicated for the topical treatment of mild to moderate plaque psoriasis in adults 18 years and older.

Launch Date

2.72159998E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1100 pg/mL
38 μg 3 times / week multiple, oral
dose: 38 μg
route of administration: Oral
experiment type: MULTIPLE
co-administered: PACLITAXEL
CALCITRIOL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
73.1799999999999 pg/mL
3 ug/g 2 times / day multiple, topical
dose: 3 ug/g
route of administration: topical
experiment type: multiple
co-administered:
CALCITRIOL plasma
Homo sapiens
population: unhealthy
age: Adolescents
sex: F+M
food status:
75.74 pg/mL
3 ug/g single, topical
dose: 3 ug/g
route of administration: topical
experiment type: single
co-administered:
CALCITRIOL plasma
Homo sapiens
population: unhealthy
age: Adolescents
sex: F+M
food status:
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
8100 pg × h/mL
38 μg 3 times / week multiple, oral
dose: 38 μg
route of administration: Oral
experiment type: MULTIPLE
co-administered: PACLITAXEL
CALCITRIOL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
737.74 pg*h/mL
3 ug/g 2 times / day multiple, topical
dose: 3 ug/g
route of administration: topical
experiment type: multiple
co-administered:
CALCITRIOL plasma
Homo sapiens
population: unhealthy
age: Adolescents
sex: F+M
food status:
764.74 pg*h/mL
3 ug/g single, topical
dose: 3 ug/g
route of administration: topical
experiment type: single
co-administered:
CALCITRIOL plasma
Homo sapiens
population: unhealthy
age: Adolescents
sex: F+M
food status:
549.29 pg*h/mL
3 ug/g 2 times / day multiple, topical
dose: 3 ug/g
route of administration: topical
experiment type: multiple
co-administered:
CALCITRIOL plasma
Homo sapiens
population: unhealthy
age: Adolescents
sex: F+M
food status:
575.12 pg*h/mL
3 ug/g single, topical
dose: 3 ug/g
route of administration: topical
experiment type: single
co-administered:
CALCITRIOL plasma
Homo sapiens
population: unhealthy
age: Adolescents
sex: F+M
food status:
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
25 h
38 μg 3 times / week multiple, oral
dose: 38 μg
route of administration: Oral
experiment type: MULTIPLE
co-administered: PACLITAXEL
CALCITRIOL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Effect of 1,25-dihydroxyvitamin D3 on the female reproductive system in rats.
1992 Aug
Dose-dependent effects of aluminum on osteocalcin synthesis in osteoblast-like ROS 17/2 cells in culture.
1992 Dec
Potentiation of lipopolysaccharide-induced tumor necrosis factor-alpha expression by 1,25-dihydroxyvitamin D3.
1992 Dec 1
EB1089: a new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitro.
1992 Dec 15
A prospective trial of phosphate and 1,25-dihydroxyvitamin D3 therapy in symptomatic adults with X-linked hypophosphatemic rickets.
1992 Sep
Zinc increases the activity of vitamin D-dependent promoters in osteoblasts.
2000 Apr 29
Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2.
2000 Jan
1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms.
2000 Jul
Regulation of vitamin D-1alpha-hydroxylase and -24-hydroxylase expression by dexamethasone in mouse kidney.
2000 Mar
Combination of 1alpha,25-dihydroxyvitamin D(3) with dexamethasone enhances cell cycle arrest and apoptosis: role of nuclear receptor cross-talk and Erk/Akt signaling.
2001 Dec
Failure of high doses of calcitriol and hypercalcaemia to induce apoptosis in hyperplastic parathyroid glands of azotaemic rats.
2001 Mar
1 alpha,25-Dihydroxycholecalciferol reduces rejection and improves survival in rat liver allografts.
2001 Nov
Regression of ventral striatum hypometabolism after calcium/calcitriol therapy in paroxysmal kinesigenic choreoathetosis due to idiopathic primary hypoparathyroidism.
2001 Nov
Hyperphosphatemia modestly retards parathyroid hormone suppression during calcitriol-induced hypercalcemia in normal and azotemic rats.
2002 Dec
Demonstration of UVB-induced synthesis of 1 alpha,25-dihydroxyvitamin D3 (calcitriol) in human skin by microdialysis.
2003 Apr
Effects of Seocalcitol (EB1089) on nitrosomethyl urea-induced rat mammary tumors.
2003 Aug
Gene expression of vitamin D hydroxylase and megalin in the remnant kidney of nephrectomized rats.
2003 Aug
9-cis retinoic acid accelerates calcitriol-induced osteocalcin production and promotes degradation of both vitamin D receptor and retinoid X receptor in human osteoblastic cells.
2003 Aug 15
Comparison of the gene expression profiles of monocytic versus granulocytic lineages of HL-60 leukemia cell differentiation by DNA microarray analysis.
2003 Aug 15
Vitamin D enhances mitogenesis mediated by keratinocyte growth factor receptor in keratinocytes.
2003 Jun 1
1alpha,25(OH)2D3 causes a rapid increase in phosphatidylinositol-specific PLC-beta activity via phospholipase A2-dependent production of lysophospholipid.
2003 May
Vitamin D inhibits G1 to S progression in LNCaP prostate cancer cells through p27Kip1 stabilization and Cdk2 mislocalization to the cytoplasm.
2003 Nov 21
Previtamin D3 with a trans-fused decalin CD-ring has pronounced genomic activity.
2003 Sep 12
Unique regulation of SOST, the sclerosteosis gene, by BMPs and steroid hormones in human osteoblasts.
2004 Aug
Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency.
2004 Aug
Calcitriol-induced prostate-derived factor: autocrine control of prostate cancer cell growth.
2004 Dec 20
Targacept active conformation search: a new method for predicting the conformation of a ligand bound to its protein target.
2004 Dec 30
Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism.
2004 Feb
Structural determinants for vitamin D receptor response to endocrine and xenobiotic signals.
2004 Jan
Retinoblastoma protein and CCAAT/enhancer-binding protein beta are required for 1,25-dihydroxyvitamin D3-induced monocytic differentiation of HL60 cells.
2004 Jan 1
Differential regulation of osteogenic marker gene expression by Wnt-3a in embryonic mesenchymal multipotential progenitor cells.
2004 Jun
Leptin corrects increased gene expression of renal 25-hydroxyvitamin D3-1 alpha-hydroxylase and -24-hydroxylase in leptin-deficient, ob/ob mice.
2004 Mar
Improved anemia and reduced erythropoietin need by medical or surgical intervention of secondary hyperparathyroidism in hemodialysis patients.
2004 May
The functional consequences of cross-talk between the vitamin D receptor and ERK signaling pathways are cell-specific.
2004 Nov 5
Calcium and calcitriol prophylaxis attenuates posttransplant bone loss.
2004 Oct 27
Role of uncoupling protein 2 (UCP2) expression and 1alpha, 25-dihydroxyvitamin D3 in modulating adipocyte apoptosis.
2004 Sep
Modulation of CYP27B1 and CYP24 mRNA expression in bone is independent of circulating 1,25(OH)2D3 levels.
2005 Apr
Daily or intermittent calcitriol administration during growth hormone therapy in rats with renal failure and advanced secondary hyperparathyroidism.
2005 Apr
Molecular and functional comparison of 1,25-dihydroxyvitamin D(3) and the novel vitamin D receptor ligand, lithocholic acid, in activating transcription of cytochrome P450 3A4.
2005 Apr 1
1,25-Dihydroxyvitamin D3 stimulates cyclic vitamin D receptor/retinoid X receptor DNA-binding, co-activator recruitment, and histone acetylation in intact osteoblasts.
2005 Feb
Human bladder as a novel target for vitamin D receptor ligands.
2005 Feb
Amphiregulin is a novel growth factor involved in normal bone development and in the cellular response to parathyroid hormone stimulation.
2005 Feb 4
Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo.
2005 Jan 28
Regulation of the human vitamin D3 receptor promoter in breast cancer cells is mediated through Sp1 sites.
2005 Jan 31
Vitamin D and phosphate regulate fibroblast growth factor-23 in K-562 cells.
2005 Jun
Mechanism and function of high vitamin D receptor levels in genetic hypercalciuric stone-forming rats.
2005 Mar
Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients.
2005 Mar
Regulation of renal calcium receptor gene expression by 1,25-dihydroxyvitamin D3 in genetic hypercalciuric stone-forming rats.
2005 May
5alpha-dihydrotestosterone inhibits 1alpha,25-dihydroxyvitamin D3-induced expression of CYP24 in human prostate cancer cells.
2005 May 15
Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
2005 Sep 1
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment:: The recommended initial dose of Calcitriol Injection, depending on the severity of the hypocalcemia and/or secondary hyperparathyroidism, is 1 mcg (0.02 mcg/kg) to 2 mcg administered intravenously three times weekly, approximately every other day. Doses as small as 0.5 mcg and as large as 4 mcg three times weekly have been used as an initial dose. Apply Calcitriol Ointment to affected areas twice daily, morning and evening. The maximum weekly dose should not exceed 200 grams. Calcitriol Ointment is not for oral, ophthalmic or intravaginal use.
Mice: Trans-calcitriol at 1.0, 2.0, and 4.0 mg/kg did not elicit any clinical effects after a single oral dose followed by 14 days of observation.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:54:08 UTC 2021
Edited
by admin
on Fri Jun 25 20:54:08 UTC 2021
Record UNII
FXC9231JVH
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CALCITRIOL
EP   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
CALCITRIOL [WHO-DD]
Common Name English
CALCITRIOL [MART.]
Common Name English
VECTICAL
Brand Name English
CALCITRIOL [VANDF]
Common Name English
ROCALTROL
Brand Name English
CALCIJEX
Brand Name English
CALCITRIOL [USP MONOGRAPH]
Common Name English
CALCITRIOL [EP MONOGRAPH]
Common Name English
(1S,3R,5Z,7E)-9,10-SECOCHOLESTA-5,7,10-TRIENE-1,3,25-TRIOL
Common Name English
CALCITRIOL [USP-RS]
Common Name English
RO-21-5535
Code English
CALCITRIOL [JAN]
Common Name English
RO-215535
Code English
CALCITRIOL [HSDB]
Common Name English
CALCITRIOL [ORANGE BOOK]
Common Name English
CALCITRIOL [INN]
Common Name English
1,25-HYDROXYLATED VITAMIN D
Common Name English
1,25-DIHYDROXYVITAMIN D3
Common Name English
RO 21-5535
Code English
CALCITRIOL [USAN]
Common Name English
CALCITRIOL [MI]
Common Name English
9,10-SECOCHOLESTA-5,7,10(19)-TRIENE-1,3,25-TRIOL, (1.ALPHA.,3.BETA.,5Z,7E)-
Common Name English
(5Z,7E)-9,10-SECOCHOLESTA-5,7,10(19)-TRIENE-1.ALPHA.,3.BETA.,25-TRIOL
Common Name English
1,25-DIHYDROXYCHOLECALCIFEROL, (1ALPHA)-
Common Name English
Classification Tree Code System Code
NDF-RT N0000006996
Created by admin on Fri Jun 25 20:54:08 UTC 2021 , Edited by admin on Fri Jun 25 20:54:08 UTC 2021
WHO-VATC QD05AX03
Created by admin on Fri Jun 25 20:54:08 UTC 2021 , Edited by admin on Fri Jun 25 20:54:08 UTC 2021
NCI_THESAURUS C39713
Created by admin on Fri Jun 25 20:54:08 UTC 2021 , Edited by admin on Fri Jun 25 20:54:08 UTC 2021
LOINC 1649-3
Created by admin on Fri Jun 25 20:54:08 UTC 2021 , Edited by admin on Fri Jun 25 20:54:08 UTC 2021
LIVERTOX 140
Created by admin on Fri Jun 25 20:54:08 UTC 2021 , Edited by admin on Fri Jun 25 20:54:08 UTC 2021
NDF-RT N0000006996
Created by admin on Fri Jun 25 20:54:08 UTC 2021 , Edited by admin on Fri Jun 25 20:54:08 UTC 2021
WHO-ATC A11CC04
Created by admin on Fri Jun 25 20:54:08 UTC 2021 , Edited by admin on Fri Jun 25 20:54:08 UTC 2021
NDF-RT N0000006996
Created by admin on Fri Jun 25 20:54:08 UTC 2021 , Edited by admin on Fri Jun 25 20:54:08 UTC 2021
NDF-RT N0000006996
Created by admin on Fri Jun 25 20:54:08 UTC 2021 , Edited by admin on Fri Jun 25 20:54:08 UTC 2021
LOINC 14566-4
Created by admin on Fri Jun 25 20:54:08 UTC 2021 , Edited by admin on Fri Jun 25 20:54:08 UTC 2021
NDF-RT N0000175908
Created by admin on Fri Jun 25 20:54:08 UTC 2021 , Edited by admin on Fri Jun 25 20:54:08 UTC 2021
WHO-VATC QA11CC04
Created by admin on Fri Jun 25 20:54:08 UTC 2021 , Edited by admin on Fri Jun 25 20:54:08 UTC 2021
WHO-ATC D05AX03
Created by admin on Fri Jun 25 20:54:08 UTC 2021 , Edited by admin on Fri Jun 25 20:54:08 UTC 2021
NCI_THESAURUS C1934
Created by admin on Fri Jun 25 20:54:08 UTC 2021 , Edited by admin on Fri Jun 25 20:54:08 UTC 2021
Code System Code Type Description
IUPHAR
2779
Created by admin on Fri Jun 25 20:54:08 UTC 2021 , Edited by admin on Fri Jun 25 20:54:08 UTC 2021
PRIMARY
ECHA (EC/EINECS)
250-963-8
Created by admin on Fri Jun 25 20:54:08 UTC 2021 , Edited by admin on Fri Jun 25 20:54:08 UTC 2021
PRIMARY
PUBCHEM
5280453
Created by admin on Fri Jun 25 20:54:08 UTC 2021 , Edited by admin on Fri Jun 25 20:54:08 UTC 2021
PRIMARY
WIKIPEDIA
CALCITRIOL
Created by admin on Fri Jun 25 20:54:08 UTC 2021 , Edited by admin on Fri Jun 25 20:54:08 UTC 2021
PRIMARY
MERCK INDEX
M2917
Created by admin on Fri Jun 25 20:54:08 UTC 2021 , Edited by admin on Fri Jun 25 20:54:08 UTC 2021
PRIMARY Merck Index
DRUG BANK
DB00136
Created by admin on Fri Jun 25 20:54:08 UTC 2021 , Edited by admin on Fri Jun 25 20:54:08 UTC 2021
PRIMARY
MESH
D002117
Created by admin on Fri Jun 25 20:54:08 UTC 2021 , Edited by admin on Fri Jun 25 20:54:08 UTC 2021
PRIMARY
EPA CompTox
32222-06-3
Created by admin on Fri Jun 25 20:54:08 UTC 2021 , Edited by admin on Fri Jun 25 20:54:08 UTC 2021
PRIMARY
INN
4393
Created by admin on Fri Jun 25 20:54:08 UTC 2021 , Edited by admin on Fri Jun 25 20:54:08 UTC 2021
PRIMARY
ChEMBL
CHEMBL846
Created by admin on Fri Jun 25 20:54:08 UTC 2021 , Edited by admin on Fri Jun 25 20:54:08 UTC 2021
PRIMARY
DRUG CENTRAL
466
Created by admin on Fri Jun 25 20:54:08 UTC 2021 , Edited by admin on Fri Jun 25 20:54:08 UTC 2021
PRIMARY
NCI_THESAURUS
C330
Created by admin on Fri Jun 25 20:54:08 UTC 2021 , Edited by admin on Fri Jun 25 20:54:08 UTC 2021
PRIMARY
HSDB
3482
Created by admin on Fri Jun 25 20:54:08 UTC 2021 , Edited by admin on Fri Jun 25 20:54:08 UTC 2021
PRIMARY
EVMPD
SUB06047MIG
Created by admin on Fri Jun 25 20:54:08 UTC 2021 , Edited by admin on Fri Jun 25 20:54:08 UTC 2021
PRIMARY
USP_CATALOG
1086301
Created by admin on Fri Jun 25 20:54:08 UTC 2021 , Edited by admin on Fri Jun 25 20:54:08 UTC 2021
PRIMARY USP-RS
RXCUI
1894
Created by admin on Fri Jun 25 20:54:08 UTC 2021 , Edited by admin on Fri Jun 25 20:54:08 UTC 2021
PRIMARY RxNorm
FDA UNII
FXC9231JVH
Created by admin on Fri Jun 25 20:54:08 UTC 2021 , Edited by admin on Fri Jun 25 20:54:08 UTC 2021
PRIMARY
LACTMED
Calcitriol
Created by admin on Fri Jun 25 20:54:08 UTC 2021 , Edited by admin on Fri Jun 25 20:54:08 UTC 2021
PRIMARY
CAS
32222-06-3
Created by admin on Fri Jun 25 20:54:08 UTC 2021 , Edited by admin on Fri Jun 25 20:54:08 UTC 2021
PRIMARY
Related Record Type Details
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
EP
BASIS OF STRENGTH->SUBSTANCE
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
SALT/SOLVATE -> PARENT
BINDER->LIGAND
BINDING
Related Record Type Details
PARENT -> METABOLITE ACTIVE
The conversion of calcidiol to calcitriol is catalyzed by the enzyme 25-hydroxyvitamin D3 1-alpha-hydroxylase (CYP27B1).
METABOLITE INACTIVE -> PARENT
MAJOR
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC